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ABSTRACT: During influenza infection, hemagglutinins (HAs) on the viral
surface bind to sialic acids on the host cell’s surface. While all HAs bind sialic
acids, human influenza targets terminal α2,6 sialic acids and avian influenza
targets α2,3 sialic acids. For interspecies transmission (zoonosis), HA must
mutate to adapt to these differences. Here, multivalent gold nanoparticles
bearing either α2,6- or α2,3-sialyllactosamine have been developed to
interrogate a panel of HAs from pathogenic human, low pathogenic avian,
and other species’ influenza. This method exploits the benefits of multivalent
glycan presentation compared to monovalent presentation to increase affinity
and investigate how multivalency affects selectivity. Using a library-orientated
approach, parameters including polymer coating and core diameter were
optimized for maximal binding and specificity were probed using galactosylated
particles and a panel of biophysical techniques [ultraviolet−visible spectroscopy,
dynamic light scattering, and biolayer interferometry]. The optimized particles
were then functionalized with sialyllactosamine and their binding analyzed against a panel of HAs derived from pathogenic influenza
strains including low pathogenic avian strains. This showed significant specificity crossover, which is not observed in monovalent
formats, with binding of avian HAs to human sialic acids and vice versa in agreement with alternate assay formats. These results
demonstrate that precise multivalent presentation is essential to dissect the interactions of HAs and may aid the discovery of tools for
disease and zoonosis transmission.
■ INTRODUCTION
Worldwide, annual epidemics of seasonal influenza are
estimated to result in 3−5 million cases of severe illness, and
up to 650,000 deaths annually are associated with respiratory
diseases from seasonal influenza.1 While influenza A and B
viruses cause seasonal epidemics, only A types have been
evidenced to cause pandemics. Influenza A viruses are
classified into subtypes according to the combination of
proteins on their surface; hemagglutinins (HA) and
neuraminidases (NA)for example, the H1N1 strain
pandemic in 2009.2 During infection, influenza virus particles
display trimeric HAs that bind to sialosides on the surface of
their host cells to facilitate internalization. While all influenza
strains bind sialosides, human strains preferentially bind to
terminal α2,6 sialic acids, whereas avian influenza viruses show
preference for α2,3 sialic acids.3,4 Zoonosis (interspecies
transmission) can occur due to mutations in the HA, enabling
a switch from α2,3 to α2,6. This allows avian influenza to infect
humans, and often occurs in porcine (pig) hosts, which present
both α2,3 to α2,6 sialosides in their respiratory tracts.5−7
Humans can be infected with avian, porcine, and other
zoonotic influenza viruses including avian influenza subtypes;
H5N1, H7N9, and H9N2 and swine flu virus subtypes; H1N1
(swine flu pandemic 2009), H1N2, and H3N2.8 It has also
emerged that N-glycolyl modifications (in addition to N-
acetyl) play a significant role in species-dependent binding9
and that influenza can bind phosphorylated, non-sialylated
glycans determined against an array of N-linked glycans from
human lungs,10 suggesting that other glycans are also involved,
or potential targets during infection.11 Therefore, the study of
HA interactions with sialic acids is essential to increase our
understanding of this global pathogen and to help guide the
discovery of new diagnostics and treatments.
The binding affinity of a HA toward an individual sialoside is
weak (Kd ≈ 2 mM),12 but because of the multivalent
presentation of both the HA (∼200−1000 copies/virus) and
the dense layer of sialic acids on the cell surface,13 the affinity is
significantly increased by the cluster glycoside effect.14 Hence,
in vivo, HAs engage with cell−surface sialic acids which are not
presented as free molecules in solution, but rather multivalent
ensembles as in the glycocalyx. Strategies to probe and dissect
HA function should reproduce this multivalent environment to
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be truly predictive. There are many examples where multi-
valent materials, in particular polymers, have been used to
engage with carbohydrate binding proteins, with most studies
focusing on plant lectins, which are of limited biomedical
relevance.15−19
Whitesides and co-workers synthesized sialic acid containing
glycopolymeric inhibitors of influenza virus X-31 via a poly(N-
acrylyloxy succinimide) reactive scaffold. Using hemagglutina-
tion and enzyme-linked immunosorbent assays, the inhibitory
activity of these polymers were found to be between 103 and
106 times greater than the free glycan.20,21 However, the effect
of the linkage was not examined. Miura and co-workers
synthesized 2,3- and 2,6-sialyllactose-functional glycopolymers
that were able to recognize two different influenza strains.
They found that 2,6-sialyllactose-functional glycopolymers
inhibited hemagglutination caused by H3N2 (A/Aichi/2/68)
but not H1N1 (A/Puerto Rico/8/34); conversely, 2,3-
sialyllactose-functional glycopolymers inhibited aggregation
caused by the H1N1 strain but not the H3N2.22 The density
and polymer length were found to affect the interaction with
the virus. Trivalent presentation of 2,3 sialic acids was
sufficient to give >400 fold increase in inhibitory activity
against H3 influenzas.23 Godula and co-workers developed a
microarray platform for the evaluation of virus binding based
on 2,6- and 2,3-sialyllactose glycopolymers, which showed
discrimination between different strains, with H3N2 (A/Aichi/
2/68) binding exclusively to 2,6-siallylactose glycopolymers,
whereas H1N1 (A/Puerto Rico/8/34) bound to both 2,3- and
2,6-sialyllactose polymers.24 In addition to the nature of the
sialic acid, the 3-D presentation is a crucial determinant with
bivalent ligands showing wide affinity trends based only on
separation,25 for example, H3N2 strains have evolved
specificity related to the length of the sialosides linker.26
Furthermore, linear sialic acid polymers were found to be more
potent inhibitors than dendritic.27
Gibson and co-workers have previously developed multi-
valent gold/polymer hybrids to dissect glycan binding
interactions.28−31 Reversible addition fragmentation chain
transfer (RAFT) polymerization was used to produce tele-
chelic polymers that have a gold immobilization site at one end
(masked thiol) and a glycan installation site (an amine reactive
pentafluorophenyl group) at the other end. The polymer linker
was found to be important, ensuring a stable formulation and
fast response readout.28,30 The use of gold nanoparticle cores,
exploiting their unique aggregation-induced red-blue color
shift, provides label-free readouts. This has been used for the
discrimination of human (H3N2) and avian (H5N1) influenza
using PEGylated gold particles presenting trivalent α2,6 sialic
acid ligands.32 Fairbanks and co-workers investigated the
interaction of HAs and whole viruses with gold nanoparticles
decorated with biantennary sialyloligosaccharides (α2,6
linked) extracted from egg yolk. Selectivity was observed
between two H1N1 strains, A/New Caledonia/20/1999 and
A/Puerto Rico/8/34, which have specificity toward α2,6 sialic
acid and α2,3 sialic acid, respectively.33 De Geest and co-
workers immobilized α2,6 sialic acid pendant glycopolymers
on AuNPs and observed an interaction with inactivated H1N1
(A/Puerto Rico/8/34) viruses as determined by DLS;
however, the selectivity compared with other strains was not
investigated.34 Furthermore, Papp et al. showed the importance
of gold core size on the efficiency of virus inhibitions with 14
nm particles having higher binding affinity than 2 nm
particles.35 The gold particle size enables the generation of
large signal responses as well as multivalency; therefore, it is
essential to optimize the core size, linker, and glycan.36 Lipid
bilayers and dendrimer scaffolds have also been employed to
probe or inhibit hemagglutinin binding.37,38
Considering the above, the aim of this work was to develop a
multivalent nanoparticle platform to dissect the binding trends
of influenza HAs toward multivalent sialic acid isomers. A
library-oriented screen of 27 nanoparticle formulations was
used to identify the optimum size and linker length, and then
translated to enable 2,3- and 2,6-sialyllactosamine attachment
to multivalent gold nanoparticles. The binding affinities of
these particles were evaluated by colorimetric aggregation
assays, dynamic light scattering (DLS) and biolayer inter-
ferometry (BLI) to ensure the whole binding landscape was
probed. A panel of eight HAs, including human and avian,
were interrogated with the particles, and it was demonstrated
that the multivalent presentation enables significant cross-
binding between human and avian strains.
■ EXPERIMENTAL SECTION
Materials. All chemicals were used as supplied unless otherwise
stated. N-Hydroxyethyl acrylamide (HEA) (97%), 4,4′-azobis(4-
cyanovaleric acid) (ACVA) (98%), mesitylene (reagent grade),
triethylamine (>99%), sodium citrate tribasic dihydrate (>99%),
gold(III) chloride trihydrate (99.9%), and ammonium carbonate
(reagent grade) were all purchased from Sigma-Aldrich. D(+)-
Galactosamine hydrochloride (99%) was purchased from Acros
Organics. 3′-Sialyllactose and 6′-sialyllactose were purchased from
Carbosynth. 2-(Dodecylthiocarbonothioylthio)-2-methylpropionic
acid pentafluorophenyl ester was synthesized as previously outlined
by Richards and Gibson.28 Soybean agglutinin (SBA) and wheat germ
agglutinin (WGA) were purchased from Vector Laboratories. The
following reagents were obtained through BEI resources, NIAID,
NIH: H1 HA protein from influenza virus, A/California/07/2009
(H1N1)pdm09, recombinant from baculovirus, NR-44074, H2 HA
protein from influenza virus, A/Singapore/1/1957 (H2N2), recombi-
nant from baculovirus, NR-2668, H3 HA protein from influenza virus,
A/Uruguay/716/2007 (H3N2), recombinant from baculovirus, NR-
15168, H4 HA protein from influenza virus, A/mallard/Alberta/455/
2015 (H4N6), recombinant from baculovirus, NR-51128, H5 HA
protein from influenza virus, A/duck/Hunan/795/2002 (H5N1),
recombinant from baculovirus, NR-43739, H7 HA protein from
influenza virus, A/Canada/rv444/2004 (H7N3), recombinant from
baculovirus, NR-43740, H9 HA protein from influenza virus, A/Hong
Kong/33982/2009 (H9N2), recombinant from baculovirus, NR-
41792 and H10 HA protein with C-terminal histidine tag from
influenza virus, A/harbor seal/Germany/1/2014 (H10N7), recombi-
nant from baculovirus, NR-50172. Clear and black half are 96-well
plates that were purchased from Greiner Bio-One. Streptavidin (SA)
biosensors were purchased from ForteBio. Lectins and HAs were
biotinylated using EZ-Link sulfo-NHS-LC-biotin reagent from
Thermo Fisher Scientific using standard procedure (20-fold molar
excess of biotin reagent, conjugation performed in phosphate-buffered
saline (PBS) buffer and isolated using Amicon Ultra-0.5 mL 3000
MWCO centrifugal filters from Merck Millipore).
Physical and Analytical Methods. 1H NMR spectra were
recorded on Bruker DPX-300 and DPX-400 spectrometers using
deuterated solvents purchased from Sigma-Aldrich. Chemical shifts
are reported relative to residual non-deuterated solvent. Size exclusion
chromatography (SEC) was carried out in dimethylformamide
(DMF) and run on an Agilent 1260 Infinity II-MDS instrument
equipped with differential refractive index, dual wavelength UV
detectors, viscometry and light scattering detectors. The system was
equipped with 2× PLgel mixed D columns (300 × 7.5 mm) and a
PLgel 5 μm guard column. The eluent is DMF with 5 mM NH4BF4
additive. Samples were run at 1 mL·min−1 at 50 °C. Poly(methyl
methacrylate) (Agilent EasiVials) were used for calibration. Analyte
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samples were filtered through a nylon filter with 0.22 μm pore size
before injection. Experimental molar mass (Mn,SEC) and dispersity
(D̵) values of synthesized polymers were determined by conventional
calibration using Agilent SEC/SEC software. The calibration range is
500−2,000,000 Da.
Lectin-Induced Aggregation Studies by Absorbance. A
stock solution of lectin was made (0.1 mg·mL−1 for SBA and 1 mg·
mL−1 for WGA) in 10 mM HEPES buffer with 0.15 M NaCl, 0.1 mM
CaCl2, and 0.01 mM MnCl2. A serial dilution (25 μL) was made up in
the same buffer in a clear, flat bottom, half area 96-well microtiter
plate. GlycoAuNPs (250 μL) were added to each well and incubated
at room temperature for 30 min. After 30 min, an absorbance
spectrum was recorded from 450 to 700 nm with 10 nm intervals.
Biolayer Interferometry. BLI was carried out on ForteBio Octet
Red96 (ForteBio, USA). Assays were performed in black 96-well half
area plates. Assays were carried out at 30 °C and agitated at 1000 rpm.
SA biosensor tips (ForteBio, USA) were hydrated in milliQ H2O
water for at least 10 min prior to use. A stable baseline was established
in milliQ water for 1 min. The biosensors were functionalized by
loading with 10 μg/mL biotinylated lectin or HA in PBS for 5 min
followed by a 1 min equilibration step in 10 mM HEPES with 0.15 M
NaCl and 0.1 mM CaCl2 and MnCl2 to remove any unbound protein
and to establish a stable baseline. Following protein immobilization,
the binding association with galactosylated and sialylated AuNPs was
carried out in 10 mM HEPES with 0.15 M NaCl and 0.1 mM CaCl2
and MnCl2 for 10 min followed by dissociation in 10 mM HEPES
with 0.15 M NaCl and 0.1 mM CaCl2 and MnCl2 for 10 min.
Synthetic Section. Polymerization of Hydroxyethyl Acrylamide
Using PFP-DMP. HEA (0.5 g, 4.34 mmol), pentafluorophenyl 2-
(dodecylthiocarbonothioylthio)-2-methylpropionic acid (PFP-DMP)
(0.092 g, 0.17 mmol), and ACVA (0.0097 g, 0.034 mmol) were
dissolved in 50:50 toluene/methanol (4 mL). Mesitylene (150 μL)
was added as an internal reference. An aliquot was taken for NMR
analysis in CDCl3. The solution was degassed under N2 for 30 min.
The reaction was stirred at 70 °C for 90 min. An aliquot was taken for
NMR analysis in MeOD. The reaction was rapidly cooled in liquid
nitrogen and precipitated into diethyl ether. The polymer was
reprecipitated into diethyl ether from methanol twice to yield a yellow
polymer product that was dried under vacuum. 96% conversion by
NMR, Mn (theoretical) = 3400 g·mol
−1 Mn (SEC) = 5800 g·mol
−1
Mn/Mw (SEC) = 1.16.
Gold Nanoparticle Synthesis. Gold nanoparticles of differing sizes
were synthesized by the method developed by Bastuś et al.39 A
solution of 2.2 mM sodium citrate in Milli-Q water (150 mL) was
heated under reflux for 15 min under vigorous stirring. After boiling
had commenced, 1 mL of HAuCl4 (25 mM) was injected. The color
of the solution changed from yellow to bluish gray and then to soft
pink in 10 min. Immediately after the synthesis of the Au seeds and in
the same reaction vessel, the reaction was cooled until the
temperature of the solution reached 90 °C. Then, 1 mL of HAuCl4
solution (25 mM) was injected. After 30 min, the reaction was
finished. This process was repeated twice. After that, the sample was
diluted by extracting 55 mL of the sample and adding 53 mL of
MilliQ water and 2 mL of 60 mM sodium citrate. This solution was
then used as a seed solution, and the process was repeated a further 7
times. Generations 2, 5, and 8 were used for this study (Table 2).
■ RESULTS AND DISCUSSION
To access multivalent glycosylated gold nanoparticles, RAFT
polymerization was employed to synthesize telechelic poly(N-
hydroxyethyl acrylamide) (PHEA) ligands suitable for both
nanoparticle immobilization, and capture of glycans via a
terminal pentafluoroethyl ester (PFP),28,30,31,40 (Figure 1A). A
range of degrees of polymerization (DP) was targeted from
DP10−DP50 by varying the [M]/[CTA] ratio. The polymers
were characterized by SEC confirming narrow dispersity
(Figure 1C and Table 1). 2-Deoxy-2-amino galactosamine
was conjugated to the ω-terminal PFP, which also removes the
dithiocarbonate to reveal a thiol for subsequent AuNP
conjugation. 19F NMR (Figure 1D) was used to confirm
displacement of the PFP group. Note, GalNH2 was chosen as
the glycan to conduct initial screening, before progressing to
the sialic acid particles (vide infra).
To access a range of gold nanoparticles of defined size, the
kinetically controlled seeded growth strategy based on the
Turkevich/Frens method via the reduction of HAuCl4 by
sodium citrate was used.39 This involved a growth process
leading to the enlargement of presynthesized 10 nm gold seeds
via the surface-catalyzed reduction of Au3+ by sodium citrate
(Figure 1B). This was characterized by UV−vis spectroscopy
(Figure 1E), DLS (Figure 1F), and transmission electron
microscopy (TEM) (Figure 1G−I). The three different
nanoparticle sizes were coated with the nine different polymers
to generate a diverse library of 27 multivalent glyconanopar-
ticles, this convergent strategy maximized structural diversity.
DLS measurements showed an increase in hydrodynamic
diameter, along with a red-shift in the SPR peak (λmax), both
Table 1. Polymers Prepared in This Study
polymer [M]/[CTA]a conversion (%)b Mn(NMR) (g·mol
−1)b Mn(SEC) (g·mol
−1)c Mw/Mn
c
Gal-PHEA10 10 96 1600 2600 1.12
Gal-PHEA15 15 99 2200 3300 1.16
Gal-PHEA20 20 97 2800 4200 1.16
Gal-PHEA25 25 98 3600 5800 1.16
Gal-PHEA30 30 95 3800 7700 1.13
Gal-PHEA35 35 97 4600 9500 1.14
Gal-PHEA40 40 98 5000 8900 1.15
Gal-PHEA45 45 94 5700 9200 1.15
Gal-PHEA50 50 92 5800 10,300 1.15
aFeed ratio of monomer to chain-transfer agent. bDetermined by 1H NMR. cDetermined by SEC in dimethylformamide using poly(methyl
methacrylate) standards. Mw, weight average molecular weight; Mn, number average molecular weight.
Table 2. Nanoparticles Synthesized and Characterization
diameter (nm)
particle generationa λSPR
b ASPR/A450
b UV−visc DLSd
Au30 2 523 1.84 30 28.2 ± 0.9
Au50 5 531 2.00 50 48.8 ± 0.4
Au70 7 540 2.05 68 72.5 ± 1.2
aGeneration of nanoparticles used from the seeding synthetic
methodology (see Figure S1). bMaximum absorption wavelength
from the surface plasmon resonance band of the particles and
characteristic ratio were used for diameter estimation. cEstimated
using the method of Haiss et al.41 from UV−vis. dDiameter from DLS
± standard error from three measurements.
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consistent with polymer coating. X-ray photoelectron spec-
troscopy (XPS) was used to confirm polymer coating on
AuNPs by increased N 1s (from amide) as well as C 1s signals
(Supporting Information, Tables S1 and S2, Figures S2−S5).
To enable protein binding studies, it was essential to first
screen the library for colloidal stability in the buffer to prevent
false positives in aggregation screens. Both particle size and
polymer length impact this, and it is a crucial step in any
binding assay. The galactose functional particles were screened
for aggregation stability by observing the increase in Abs700. A
NaCl gradient (0−1 M) as well as HEPES buffer were tested
(full data set is in the Supporting Information, Figure S6).
From this, it was clear that for all particle sizes, ligands with a
DP above 25 were essential to obtain colloidally stable
particles, in line with the previous reports.28,42 From this
screen, it was decided to study protein binding using particles
coated with polymers DP25−DP50 to avoid false positives due
to buffer-induced aggregation. To screen for binding, the
model lectin, SBA was used to validate the methods and to
establish which particle structural requirements gave the
strongest outputs, Figure 2.
Figure 2A shows the outputs of this aggregation screen as a
function of polymer ligand length and nanoparticle size. Full
dose-dependent curves are in the Supporting Information
(Figure S6). For all polymer lengths, the largest changes were
seen for the shortest polymer chain length (DP25) with a step-
wise decrease as polymer length increases, and the biggest (70
nm) particles gave the largest outputs. Although the
aggregation assay used above provides a convenient output
of binding, it cannot rule out the case where lectins bind but
fail to agglutinate. For example, the longer polymer linkers are
likely able to bind to SBA, but also provide a steric block
against agglutination, highlighting the need for tuning of these
parameters. Therefore, a second assay using BLI was
developed.43 In short, biotinylated SBA was immobilized
onto SA functional BLI sensors (ForteBio) (Figure 2B) and
the nanoparticles exposed to this. As BLI is mass sensitive,
individual glycans do not give a strong signal, but when
coupled in this nanoparticle format, larger signals are obtained.
In addition, cluster glycoside enhancement is achieved and is a
key benefit of this approach. The total BLI signal as a function
of particle parameters is shown in Figure 2D. The shorter
polymers at all particle sizes gave the largest outputs; however,
there was little binding observed to the SBA when DP50
polymers were used. This suggests that the lower density of
longer polymers is reducing overall affinity and multivalent
enhancement. Brewer and co-workers,44,45 and Godula and
Bertozzi46 observed valency-dependent binding of SBA to
GalNAc-functionalized mucins/mucin-like materials. Further-
more, Gibson and co-workers have previously shown density-
dependent binding of SBA to heterogenous AuNPs.31 Larger
particles gave more signal, but it should be noted that BLI is a
mass-weighted analysis method and hence only qualitative
trends can be compared for nanoparticle size.
Figure 1. Synthetic strategy and characterization of polymers and particles. (A) Synthesis of galactose terminal PHEA; (B) step growth process for
the synthesis of gold nanoparticles; (C) SEC of Gal-PHEAs; (D) 19F NMR showing displacement of the pentafluorophenyl unit; (E) UV−vis
spectroscopy of uncoated AuNPs; (F) DLS of uncoated AuNPs; (G−I) TEM of uncoated AuNPs. Scale bar = 100 nm.
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Guided by the above data, using galactose functional
nanoparticles, the primary aim of studying multivalent sialic
acid particles could be investigated on the optimized scaffold.
1-Deoxy, 1-amino, 2,3- and 2,6-sialyllactose were synthesized
by the single-step Kochetkov amination method47 (Figure 3A,
with the amination confirmed by mass spectrometry). Using
the same procedure as GalNH2, the sialyllactosamines (SLs)
were conjugated to DP25 PHEA and subsequently used to
coat 70 nm AuNPs. This single polymer/particle combination
was chosen based on the above screening (Figure 2), which
ensured that particles that generate the largest signals with
consistent grafting densities were used.
These glycoparticles were first tested against WGA, a lectin
known to have some affinity to sialic acids.48 Using UV−vis to
monitor aggregation, it appeared that both 2,3- and 2,6-
sialyllactosamines had similar affinities toward WGA (Figure
4A), which was not expected. However, parallel DLS
investigations (Figure 4B) showed 2,6-sialyllactosamine to
cluster faster and to give larger cluster sizes, which is consistent
with it having a stronger interaction than 2,3-sialyllactosamine.
BLI analysis against WGA immobilized on a surface showed
greater specificity for the 2,6-sialyllactosamine compared to
2,3-sialyllactosamine, which is in line with the previous reports.
This set of analyses shows that the colorimetric changes of
glyconanoparticles are useful for comparisons of affinity, but
more detailed methods (such as the BLI) are required,
especially if unknown/new interactions are being evaluated.
The above data shows that DP25 PHEA ligands on 70 nm
particles give strong binding, and that the amidation/
conjugation methodology enables installation of sialic acid
isomers with retention of their biological binding specificities
and affinities. The particles were then taken forward into a
screen against a panel of HAs. A single nanoparticle/polymer
length combination was used to ensure that grafting density
differences did not affect the observed outcomes, where glycan
density display is likely to play a significant role.
Influenza A can be categorized by the different subtypes of
the proteins present of which there are at least 18 different HA
subtypes named H1 to H18.2 The panel of HAs used were
from the five strains with human hosts: H1 from A/California/
07/2009 (H1N1)pdm09, H2 from A/Singapore/1/1957
(H2N2), H3 from A/Uruguay/716/2007 (H3N2), H7 from,
Figure 2. Galactosylated particles and SBA binding. (A) Aggregation
of gold particles leading to red-blue color shift due to SPR band
coupling. Change in Abs700 using 500 nM SBA as a function of
coating and core size. Full binding curves from 500 to 0 nM are in the
Supporting Information, Figure S7; (B) BLI schematic, showing
capture of SBA and subsequent binding to AuNPs to generate signal.
Total binding (Δmax) as a function of coating and core size. Full
binding curves are in the Supporting Information, Figure S8.
Figure 3. Synthesis of sialylated gold nanoparticles. (A) Amination of 2,3- and 2,6- sialyllactoses using Kochetkov method; (B) reaction of DP25
PFP-PHEA with sialyllactoamines and subsequent immobilization of the polymers onto 70 nm gold nanoparticles.
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A/Canada/rv444/2004 (H7N3), and H9 from A/Hong
Kong/33982/2009 (H9N2); and two from avian hosts: H4
from A/mallard/Alberta/455/2015 (H4N6) and H5 from A/
duck/Hunan/795/2002 (H5N1); and another zoonotic strain,
H10 from A/harbor seal/Germany/1/2014 (H10N7) (seal
host), and it enables the study of pathogenic processes without
the need for intact viral particles. HAs were immobilized onto
the BLI sensors using biotin/SA (as above). BLI has been
widely used to evaluate hemagglutinin/neuraminidase function
using isolated proteins and the whole virus.49−51 Figure 5A
shows example BLI curves of 2,6-sialyllactosamine nano-
particles against the HA panel and Figure 5B shows BLI curves
of 2,3-sialyllactosamine nanoparticles. There was a difference
in response in terms of total mass captured and the rate of
binding, reiterating the range of binding affinities shown by
HAs from different pathogenic strains (low pathogenic avian
strains) when presented in a multivalent format. To enable
comparison, Figure 5C shows the maximal binding of the
particles to the HAs for both 2,3- and 2,6-sialyllactosamine-
functionalized AuNPs. A key feature here is that although
many of the avian HAs are characterized as being α2,3-
selective based on previous studies using monovalent
compounds, there is clearly cross-affinity in most cases using
our multivalent system. This shows the importance of this
study, as it shows that glycan specificity can change when in
multivalent format because of the enhancement of weak
interactions, as well as stronger ones. H9 in particular showed
significant binding to both 2,3-sialyllactosamine and 2,6-
sialyllactosamine AuNPs, indicating that it can bind to both
human and avian sialic acids, which is consistent with the virus
being of avian origins infecting a human host. This crossover in
binding has also been observed by Godula and co-workers,24
where significant binding of H1N1 (A/Puerto Rico/8/34
which transmitted into humans) was noted toward both α2,6
and α2,3 sialylated polymer microarrays. In contrast, more
discrete binding was observed with H3N2 (A/Aichi/2/68)
which bound only to α2,6 but not to α2,3 sialylated polymer
arrays (note that the specific strains were not the same as used
in this study). Furthermore, McCauley and co-workers have
investigated the mammalian transmissibility of many avian and
other zoonotic influenza strains including H7N9,49 H9N2,50
Figure 4. Interaction of SL-functionalized particles: 2,3-SL-PHEA@
AuNP (black ■), 2,6-SL-PHEA@AuNP (red ●), and Gal-PHEA@
AuNP (blue ▲) with WGA by (A) UV−vis; (B) DLS; and (C) BLI.
Figure 5. Interaction of SL-functionalized nanoparticles with a panel
of HAs using BLI. (A) 2,3-SL-PHEA@AuNP and (B) 2,6-SL-
PHEA@AuNP BLI binding curves to HA panel (H1 from A/
California/07/2009 (H1N1)pdm09, H2 from A/Singapore/1/1957
(H2N2), H3 from A/Uruguay/716/2007 (H3N2), H4 from A/
mallard/Alberta/455/2015 (H4N6), H5 from A/duck/Hunan/795/
2002 (H5N1), H7 from, A/Canada/rv444/2004 (H7N3), NR-43740,
H9 from A/Hong Kong/33982/2009 (H9N2), and H10 from A/
harbor seal/Germany/1/2014 (H10N7)); (C) comparison of the
maximal binding of 2,3-SL-PHEA@AuNP and 2,6-SL-PHEA@AuNP
to the HA panel; (D) difference (subtraction) between maximal
binding to 2,6-SL-PHEA@AuNP and 2,3-SL-PHEA@AuNP to
visualize relative binding preferences.
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and H10N852 by looking at the binding of sialylated polymers
to viruses. In particular, a panel of H9N2 viruses from different
origins were assessed for their binding to α2,6 and α2,3
sialylated polymer-functionalized BLI sensors.50 Wide-ranging
binding variability was noted to different H9N2 viruses, with
the H9N2 (A/Hong Kong/33982/2009) virus (the same H9
used in this study) showing greater binding toward α2,6
sialylated polymers over α2,3 sialylated polymers, which is in
agreement with our results here, supporting the approach
taken (dose-dependent BLI binding curves for H1 from A/
California/07/2009 (H1N1)pdm09, H7 from A/Canada/
rv444/2004 (H7N3), and H9 from H9N2 (A/Hong Kong/
33982/2009) in the Supporting Information, Figures S12−
S14). The H7N9 strain has been reported to retain its avian
affinity preference even with mutations to target human
receptors, which we also observed using this nanoparticle
system.53 To visualize these differences, Figure 5D plots the
relative binding preferences, defined as the maximal binding of
2,6-sialyllactosamine nanoparticles, minus the maximal binding
of 2,3-sialyllactosamine to each hemagglutinin. As the same
coating and same nanoparticle core was used in each case, this
enabled visualization of the differences in total particle
captured to the haemagglutinin. These results show that our
nanoparticle system generates sufficient signal amplification to
enable the evaluation of glycans for binding haemagglutinins
and to unravel the cross-affinity due to the multivalent
presentation. It is important to note that these results may be
specific to the sialyllactose ligands being employed here, which
are readily available compared to, for example, complex
branched glycans. It does show that, however, in multivalent
format both the extent of binding and relative binding between
the isomers varies between the hemagglutinins and may offer
routes to multiplexed sensing and discrimination.
■ CONCLUSIONS
Here, we have developed a multivalent nanoparticle approach
to investigate the affinity of sialic acid isomers against a panel
of influenza A HAs to map their affinity. This allows for the
probing of specificity and affinity trends while benefitting from
signal amplification due to particle size. The multivalent
nanoparticles were synthesized using polymeric ligands bearing
a glycan capture (pentafluorophenyl ester) and a gold
immobilization (thiol) termini. Initial screening of a library
of 27 nanoparticles, varying in ligand length and core diameter,
enabled identification of the optimum multivalent probe, using
a model lectin and complementary UV−vis, DLS, and BLI
analysis. 2,3- and 2,6-sialyllactosamine were conjugated to
these particles via a Kochetkov amination step, which were
then interrogated for their binding against a panel of influenza
A HAs including three mammalian strains, four avian strains,
and a zoonotic influenza strain. As expected, 2,3-sialyllactos-
amine had strong affinity toward avian strains and 2,6-
sialyllactosamine against mammalian. However, the analysis
also revealed that in multivalent format, there was significant
crossover in affinities. All avian influenzas showed affinity
toward the multivalent 2,6-sialyllactosamine particles suggest-
ing the potential for crossover due to multivalency. It is
important to note that this study does not predict zoonosis
potential, but rather highlights that multivalent nanoparticle
presentation affects the affinity/selectivity trends compared to
monovalent compounds. The identification of off-specific
binding profiles is crucial to help develop nanomaterials for
biosensing and monitoring of emerging infectious diseases.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.biomac.0c00179.
Additional nanoparticle characterization (XPS and
DLS), full UV−visible spectroscopy curves for the lectin
binding assays, and underpinning BLI binding curves
(PDF)
■ AUTHOR INFORMATION
Corresponding Author
Matthew I. Gibson − Department of Chemistry and Warwick
Medical School, University of Warwick, Coventry CV4 7AL,
U.K.; orcid.org/0000-0002-8297-1278;
Email: m.i.gibson@warwick.ac.uk
Authors
Sarah-Jane Richards − Department of Chemistry, University of
Warwick, Coventry CV4 7AL, U.K.
Alexander N. Baker − Department of Chemistry, University of
Warwick, Coventry CV4 7AL, U.K.; orcid.org/0000-0001-
6019-3412
Marc Walker − Department of Physics, University of Warwick,
Coventry CV4 7AL, U.K.
Complete contact information is available at:
https://pubs.acs.org/10.1021/acs.biomac.0c00179
Notes
The authors declare no competing financial interest.
The research data supporting this publication can be found at
http://wrap.warwick.ac.uk.
■ ACKNOWLEDGMENTS
M.I.G. holds an ERC starting grant (CRYOMAT 638661).
The Royal Society are also thanked for funding the cryo-
microscopes used in this study. BBSRC/Innovate are thanked
for funding the Specialty Glycans project BB/M02878X/1.
The BBSRC-funded MIBTP program (BB/M01116X/1) and
Iceni Diagnostics ltd are thanked for a studentship for A.N.B.
The Warwick Polymer Research Technology Platform is
acknowledged for the SEC analysis. Laura Wilkins (UoW) is
thanked for the TEM analysis. The following reagents were
obtained through BEI Resources, NIAID, NIH: H1 HA
protein from influenza virus, A/California/07/2009 (H1N1)
pdm09, recombinant from baculovirus, NR-44074, H2 HA
protein from influenza virus, A/Singapore/1/1957 (H2N2),
recombinant from baculovirus, NR-2668, H3 HA protein from
influenza virus, A/Uruguay/716/2007 (H3N2), recombinant
from baculovirus, NR-15168, H4 HA protein from influenza
virus, A/mallard/Alberta/455/2015 (H4N6), recombinant
from baculovirus, NR-51128, H5 HA protein from influenza
virus, A/duck/Hunan/795/2002 (H5N1), recombinant from
baculovirus, NR-43739, H7 HA protein from influenza virus,
A/Canada/rv444/2004 (H7N3), recombinant from baculovi-
rus, NR-43740, H9 HA protein from influenza virus, A/Hong
Kong/33982/2009 (H9N2), recombinant from baculovirus,
NR-41792 and H10 HA protein with C-terminal histidine tag
from influenza virus, A/harbor seal/Germany/1/2014
(H10N7), recombinant from baculovirus, NR-50172.
Biomacromolecules pubs.acs.org/Biomac Article
https://dx.doi.org/10.1021/acs.biomac.0c00179
Biomacromolecules 2020, 21, 1604−1612
1610
■ REFERENCES
(1) Iuliano, A. D.; Roguski, K. M.; Chang, H. H.; Muscatello, D. J.;
Palekar, R.; Tempia, S.; Cohen, C.; Gran, J. M.; Schanzer, D.;
Cowling, B. J.; Wu, P.; Kyncl, J.; Ang, L. W.; Park, M.; Redlberger-
Fritz, M.; Yu, H.; Espenhain, L.; Krishnan, A.; Emukule, G.; van
Asten, L.; Pereira da Silva, S.; Aungkulanon, S.; Buchholz, U.;
Widdowson, M.-A.; Bresee, J. S.; Azziz-Baumgartner, E.; Cheng, P.-Y.;
Dawood, F.; Foppa, I.; Olsen, S.; Haber, M.; Jeffers, C.; MacIntyre, C.
R.; Newall, A. T.; Wood, J. G.; Kundi, M.; Popow-Kraupp, T.;
Ahmed, M.; Rahman, M.; Marinho, F.; Sotomayor Proschle, C. V.;
Vergara Mallegas, N.; Luzhao, F.; Sa, L.; Barbosa-Ramírez, J.;
Sanchez, D. M.; Gomez, L. A.; Vargas, X. B.; Acosta Herrera, a.;
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